Tazobactam Sodium

Inquiry

Cat Number

API0232292

CAS Number

89785-84-2

For research use only. We do not supply to patients.

For pharmaceutical-grade products or other inquiries, please contact our experts.

Product Detail Description Scientific Support Customer Q&A

CAS Number

89785-84-2

EINECS

685-629-4

Storage

Store at 2-8°C

Synonyms

Tazobactum sodium; CL-307579; DTXSID8046030; UXA545ABTT

Molecular Formula

C10H11N4NaO5S

Molecular Weight

322.28

Smiles

C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])CN3C=CN=N3.[Na+]

Appearance

White to off-white solid powder

Melting Point

140-147°C

Boiling Point

707.1°C at 760 mmHg

Relative Density

1.92

General Description

Tazobactam sodium is a synthetic penicillanic acid sulfone derivative, a beta-lactamase inhibitor, with a triazolyl group. Its chemical structure is (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid sodium salt. Tazobactam is a white to off-white powder, soluble in water. It is a potent inhibitor of beta-lactamases.

Mechanism of Action

Tazobactam acts as a suicide inhibitor of serine beta-lactamases, including TEM, SHV, and CTX-M enzymes, by forming a stable acyl-enzyme complex. This inactivates the enzyme and prevents the hydrolysis of beta-lactam antibiotics, such as piperacillin, restoring their activity against resistant bacteria. The drug has no significant antibacterial activity of its own.

Application

Tazobactam is indicated in combination with piperacillin for the treatment of a wide range of infections, including pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, and skin and soft tissue infections, caused by beta-lactamase-producing organisms. It is effective in enhancing the activity of piperacillin against resistant gram-negative and gram-positive bacteria.

In the ACORN randomized trial comparing cefepime vs piperacillin-tazobactam in 2,511 hospitalized adults, the highest stage of acute kidney injury or death by day 14 did not differ between groups (OR 0.95, 95% CI 0.80-1.13, P=0.56). However, patients receiving cefepime experienced fewer days alive and free of delirium and coma within 14 days (mean 11.9 vs 12.2 days, OR 0.79, 95% CI 0.65-0.95). Piperacillin-tazobactam did not increase kidney injury; cefepime was associated with more neurological dysfunction.

Fig. 1 Effect Modification of the Primary and Secondary Outcomes. (Qian ET, et al., 2023)

References

Qian ET, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA. 2023;330(16):1557-1567.

Does Tazobactam Sodium require refrigerated storage as a beta‑lactamase inhibitor?

Yes, it must be stored at 2–8°C. At room temperature, rapid hydrolysis of the beta‑lactam ring and degradation of the triazole ring occur.

Is Tazobactam Sodium extremely sensitive to moisture, and how is this prevented?

Yes, it is highly hygroscopic. Our packaging includes moisture‑barrier foil bags with desiccant. Open only in low‑humidity environments under refrigeration.

What is the stability of Tazobactam Sodium after reconstitution for combination therapy with piperacillin?

Reconstituted solutions are stable for up to 24 hours under refrigeration.

How is the impurity tazobactam ring‑opened acid (a hydrolysis product) monitored?

This primary degradation product is specifically quantified using a stability‑indicating HPLC method, ensuring it remains within pharmacopoeial limits.